Sanuwave Health (SNWV) AI Stock Analysis

• Market Cap: $275.75M
• Dividend Yield: N/A
• Average Volume (3M): 113.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.16
• Revenue Growth: 61.50%
• EPS Growth: 34.99%
• Country: US
• Employees: 46
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Devices
• EPS (TTM): -0.66
• Shares Outstanding: 8,555,616
• 10 Day Avg. Volume: 241,996
• 30 Day Avg. Volume: 113,425
• PEG Ratio: 1.06
• Price to Book (P/B): -16.31
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -403.34
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 2.23
• Enterprise Value/Gross Profit: 9.90
• Enterprise Value/Ebitda: 14.70
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 56 Neutral
• Price Target: $34.00 ▲(7.19%Upside)

Sanuwave Health's stock is buoyed by strong technical analysis and positive earnings call sentiment, indicating potential growth. However, significant risks related to financial stability and valuation metrics weigh heavily on the overall score. The company's high leverage and ongoing losses are key concerns.

Sanuwave Health Business Overview & Revenue Model

Company Description

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

How the Company Makes Money

Sanuwave Health generates revenue through the sale and licensing of its medical devices and technology. The company's primary revenue streams include direct sales of its regenerative medicine devices to healthcare providers, clinics, and hospitals. Additionally, Sanuwave engages in strategic partnerships and licensing agreements with other medical technology and healthcare companies, allowing them to utilize Sanuwave's proprietary shockwave technology in their own products and treatments. These partnerships often involve upfront payments, royalties, and milestone payments, contributing to Sanuwave's earnings. The company's revenue is further supplemented by service agreements and maintenance contracts for the ongoing support and servicing of its devices.

Sanuwave Health Financial Statement Overview

Summary

Sanuwave Health shows impressive revenue growth; however, the company faces significant profitability challenges. The balance sheet is weak, with negative equity and high leverage, posing insolvency risks. Despite some improvements in cash flow, the reliance on external financing remains a concern.

Income Statement

Sanuwave Health's revenue has shown significant growth over recent years, with a TTM revenue increase of 10.9% compared to the previous annual period. However, the company remains unprofitable, recording a negative net income for the TTM. EBIT and EBITDA margins are also negative, indicating ongoing operational challenges.

Balance Sheet

The balance sheet shows a concerning financial position with negative stockholders' equity and high total liabilities. The debt-to-equity ratio is not calculable due to negative equity, and the equity ratio is also negative, indicating insolvency risks. Despite a reduction in net debt, overall leverage remains a significant risk factor.

Cash Flow

Operating cash flow has improved in recent periods, turning negative to slightly positive in the previous annual report before slipping back to negative in the TTM period. Free cash flow remains volatile but shows some signs of improvement. The company is still heavily reliant on financing activities for cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	36.19M	32.63M	20.40M	16.74M	13.01M	4.06M
Gross Profit	27.73M	24.55M	14.36M	12.41M	8.02M	2.90M
EBITDA	-4.09M	-16.56M	-9.15M	-8.00M	-18.90M	-27.38M
Net Income	-32.52M	-31.37M	-25.81M	-10.29M	-27.26M	-34.08M
Balance Sheet
Total Assets	30.86M	30.12M	22.42M	19.87M	18.62M	23.03M
Cash, Cash Equivalents and Short-Term Investments	8.50M	10.24M	1.80M	1.15M	619.00K	2.44M
Total Debt	830.00K	25.50M	31.94M	41.11M	26.20M	17.58M
Total Liabilities	48.15M	42.84M	65.59M	60.88M	57.58M	36.75M
Stockholders Equity	-17.29M	-12.72M	-43.18M	-41.01M	-38.96M	-13.72M
Cash Flow
Free Cash Flow	-700.00K	1.97M	-4.54M	-16.15M	-6.94M	-12.77M
Operating Cash Flow	-162.00K	2.46M	-4.54M	-17.17M	-6.41M	-12.72M
Investing Cash Flow	-538.00K	-490.00K	21.00K	332.00K	-529.00K	-20.05M
Financing Cash Flow	6.25M	6.35M	5.21M	17.38M	5.12M	33.45M

Sanuwave Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 31.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNWV, the sentiment is Positive. The current price of 31.72 is above the 20-day moving average (MA) of 31.11, above the 50-day MA of 30.14, and above the 200-day MA of 24.81, indicating a bullish trend. The MACD of 0.70 indicates Negative momentum. The RSI at 52.10 is Neutral, neither overbought nor oversold. The STOCH value of 64.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNWV.

Sanuwave Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VMD	80 Outperform	$279.83M	23.73	9.79%	―	19.97%	17.21%
Sector *	60 Neutral	HK$15.31B	5.72	-7.43%	4.61%	11.60%	-21.06%
SNWV	56 Neutral	$275.75M	―	0.65%	―	61.50%	34.99%
RCEL	55 Neutral	$136.67M	―	-407.50%	―	32.24%	-66.93%
MXCT		$170.47M	―	-19.62%	―	―	―
ZIMV	54 Neutral	$279.49M	―	-6.35%	―	-32.70%	94.89%
NNOX	48 Neutral	$339.85M	―	-30.11%	―	15.32%	15.73%

Sanuwave Health Corporate Events

Sanuwave Health Schedules 2025 Annual Stockholders Meeting

Sanuwave Health, Inc. has announced its 2025 Annual Meeting of Stockholders, scheduled for August 19, 2025, with a record date of July 8, 2025. The announcement highlights the company’s compliance with regulatory requirements for stockholder proposals and nominations, following the absence of a 2024 meeting, and sets deadlines for submissions to be considered for inclusion in proxy materials.

Sanuwave Health Appoints New EVP for Commercial Ops

On May 30, 2025, Sanuwave Health terminated its Chief Commercial Officer, Nanci Gilmore, without cause, and she is entitled to a severance package. Subsequently, on June 3, 2025, Dustin Libby was appointed as Executive Vice President of Commercial Operations, bringing extensive experience in scaling medical device companies, which is expected to drive growth and strengthen Sanuwave’s position in the wound care market.

Sanuwave Health Appoints Gregory Bazar to Board

On May 26, 2025, A. Michael Stolarski resigned from the Board of Directors of Sanuwave Health, Inc., effective May 27, 2025. His resignation was not due to any disagreements with the company. To fill the vacancy, Gregory Bazar was appointed to the Board and the Compensation Committee, effective May 27, 2025. Bazar received stock options as part of his compensation, which will vest quarterly over ten years.